NCT07122180

Post-Market Clinical Follow-Up of the CT3 Series Continuous Glucose Monitoring System: A 14-Day Observational Study Assessing Accuracy, Safety, and Glucose Control in Patients With Type 1 and Type 2 Diabetes Mellitus

• Status: Enrolling By Invitation
• Phase: —
• Study type: Observational
• Enrollment: 72 (estimated)
• Sponsor: MDCECRO LLC · Network
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Post market Clinical follow-up of the CT3 Series Continuous Glucose Monitoring System: A 14-Day Observational Study Assessing Accuracy, Safety, and Glucose Control in patients with Type 1 and Type 2 Diabetes Mellitus

Detailed description

To re-assess the benefits of CT3 series CGM and the risks of skin abnormalities, hypoglycaemia, hyperglycaemia so as to improve CT3 series CGM continuously.

Conditions

• Diabetes Mellitus

Interventions

Type	Name	Description
DEVICE	CT3 Series Continuous Glucose Monitoring System:	The CT3 Series CGM System is a real-time, continuous glucose monitoring device indicated for the management of diabetes in adults (age≥18 years). Interpretation of the CT3 Series CGM System results should be based on the glucose trends and several sequential readings over time. The CT3 Series CGM System also aids in the detection of episodes of hyperglycaemia and hypoglycaemia. It is intended for single-patient use. It is intended to replace fingerstick blood glucose testing for diabetes treatment decisions unless otherwise indicated

Timeline

• Start date: 2025-06-04
• Primary completion: 2025-09-17
• Completion: 2026-01-31
• First posted: 2025-08-14
• Last updated: 2025-08-22

Locations

1 site across 1 country: Latvia